Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Alzheimers & Dementia

Cognito Therapeutics

Attachments

2022: Fierce Medtech's 2021 Fierce 15
Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Alzheimers & Dementia
FDA _ Breakthrough Devices Program
Industry: Massachusetts

2021: Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimer’s Diseas
2026: Cognito Therapeutics raises $105M for neurotechnology platform for Alzheimer's
2026: Morningside Ventures, IAG Capital Partners and Starbloom Capital led the round, with participation from new investors Apollo Health Ventures and Benvolio Group, New Vintage and others.
Cambridge, Massachusetts
CEO:Brent Vaughan, Cognito Therapeutics (2022)
Cognito Therapeutics is a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease.
Founded 2016
The company’s licensed proprietary neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Edward Boyden is a non-invasive, neurostimulation therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases